TAFASITAMAB-CXIX

TAFASITAMAB-CXIX was reported 906 times

TAFASITAMAB-CXIX is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CD19 EXPRESSION DECREASED 1 0.3333
1 CD19 ANTIGEN LOSS 2 0.1250
2 BLASTOCYSTIS INFECTION 5 0.0575
3 DIALYSIS DISEQUILIBRIUM SYNDROME 1 0.0500
4 TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY 1 0.0400
5 COR PULMONALE CHRONIC 6 0.0319
6 CSF LYMPHOCYTE COUNT ABNORMAL 1 0.0278
7 CATHETER SITE THROMBOSIS 7 0.0255
8 RHODOCOCCUS INFECTION 4 0.0241
9 FULL BLOOD COUNT 1 0.0175
10 CITROBACTER TEST POSITIVE 1 0.0152
11 TUMOUR FLARE 9 0.0132
12 LYMPHOCYTIC LYMPHOMA 1 0.0120
13 C-REACTIVE PROTEIN DECREASED 7 0.0107
14 LYMPHOMA 165 0.0107
15 BACTERIAL DISEASE CARRIER 7 0.0096
16 BLOOD LACTATE DEHYDROGENASE DECREASED 3 0.0090
17 INCARCERATED INGUINAL HERNIA 1 0.0082
18 FOLLICULAR LYMPHOMA 7 0.0080
19 INFESTATION 2 0.0077
20 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED 9 0.0072
21 DIFFUSE LARGE B-CELL LYMPHOMA STAGE IV 2 0.0061
22 DIFFUSE LARGE B-CELL LYMPHOMA 42 0.0054
23 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 5 0.0053
24 PNEUMONIA ADENOVIRAL 1 0.0051
25 ENTEROCOCCAL BACTERAEMIA 5 0.0047
26 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 10 0.0045
27 TOXIC CARDIOMYOPATHY 1 0.0045
28 B-CELL SMALL LYMPHOCYTIC LYMPHOMA 1 0.0043
29 MEAN ARTERIAL PRESSURE DECREASED 1 0.0040
30 HYPERCALCAEMIA OF MALIGNANCY 1 0.0037
31 PYOMYOSITIS 1 0.0034
32 RETROPERITONEAL ABSCESS 1 0.0032
33 DISCONTINUED PRODUCT ADMINISTERED 1 0.0030
34 BLOOD CREATININE DECREASED 9 0.0029
35 TONGUE EXFOLIATION 1 0.0028
36 SYSTEMIC CANDIDA 7 0.0028
37 LYMPHOMA TRANSFORMATION 1 0.0028
38 ADMINISTRATION SITE REACTION 1 0.0026
39 POLYNEUROPATHY 29 0.0024
40 BLOOD LACTATE DEHYDROGENASE INCREASED 38 0.0024
41 METASTASES TO MENINGES 5 0.0022
42 CREATININE RENAL CLEARANCE ABNORMAL 1 0.0022
43 CYTOPENIA 26 0.0021
44 LONG QT SYNDROME 5 0.0021
45 DISEASE PROGRESSION 239 0.0020
46 HEPATITIS B 12 0.0020
47 METASTASES TO KIDNEY 1 0.0018
48 MEAN CELL HAEMOGLOBIN CONCENTRATION INCREASED 1 0.0018
49 LEFT VENTRICULAR FAILURE 6 0.0017
50 LYMPHATIC DISORDER 1 0.0017
51 CYTOMEGALOVIRUS INFECTION REACTIVATION 7 0.0016
52 IMMUNISATION REACTION 1 0.0014
53 COMA HEPATIC 1 0.0013
54 CARDIAC DYSFUNCTION 5 0.0013
55 BLOOD FIBRINOGEN INCREASED 1 0.0013
56 PELVIC MASS 1 0.0012
57 ANAL ULCER 1 0.0012
58 PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL 1 0.0012
59 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 7 0.0012
60 ABDOMINAL LYMPHADENOPATHY 1 0.0012
61 PULMONARY FUNCTION TEST DECREASED 5 0.0011
62 INTRACRANIAL MASS 1 0.0011
63 HAEMATOTOXICITY 10 0.0011
64 NEUTROPENIC INFECTION 1 0.0010
65 HEPATITIS C 12 0.0010
66 TUMOUR PSEUDOPROGRESSION 1 0.0009
67 UROSEPSIS 8 0.0009
68 TONGUE HAEMORRHAGE 1 0.0009
69 COVID-19 PNEUMONIA 10 0.0008
70 BLADDER DISCOMFORT 1 0.0008
71 PATHOLOGICAL FRACTURE 4 0.0008
72 OBSTRUCTION GASTRIC 1 0.0008
73 BRONCHOPULMONARY ASPERGILLOSIS 6 0.0008
74 BACTERAEMIA 9 0.0008
75 CYTOKINE RELEASE SYNDROME 15 0.0007
76 CARDIOMYOPATHY 11 0.0007
77 CENTRAL NERVOUS SYSTEM LYMPHOMA 1 0.0007
78 CYTOMEGALOVIRUS INFECTION 12 0.0007
79 THROMBOTIC MICROANGIOPATHY 7 0.0007
80 PERIPHERAL ARTERY OCCLUSION 1 0.0007
81 FEBRILE BONE MARROW APLASIA 3 0.0007
82 CONNECTIVE TISSUE DISORDER 1 0.0007
83 INSULIN-LIKE GROWTH FACTOR INCREASED 1 0.0007
84 HEPATIC LESION 3 0.0007
85 NOROVIRUS INFECTION 1 0.0007
86 PULMONARY SEPSIS 1 0.0007
87 ENTEROCOLITIS HAEMORRHAGIC 1 0.0007
88 PARAINFLUENZAE VIRUS INFECTION 1 0.0007
89 HYPERTHERMIA 5 0.0007
90 PERFORMANCE STATUS DECREASED 3 0.0006
91 EPSTEIN-BARR VIRUS INFECTION 4 0.0006
92 AORTIC VALVE DISEASE 1 0.0006
93 LIVER ABSCESS 2 0.0006
94 SPLENIC RUPTURE 1 0.0006
95 MALIGNANT PLEURAL EFFUSION 1 0.0006
96 ACUTE SINUSITIS 1 0.0006
97 OTORRHOEA 1 0.0006
98 PSEUDOMONAL SEPSIS 1 0.0006
99 NEOPLASM PROGRESSION 19 0.0005
100 SMALL INTESTINAL PERFORATION 1 0.0005
101 NASAL OBSTRUCTION 1 0.0005
102 METASTASES TO LUNG 6 0.0005
103 EXTRAVASATION 2 0.0005
104 HYPERCALCAEMIA 6 0.0005
105 GASTROENTERITIS 7 0.0005
106 EAR SWELLING 1 0.0005
107 HYPERPHOSPHATAEMIA 1 0.0005
108 HYPOGAMMAGLOBULINAEMIA 3 0.0005
109 TONGUE BLISTERING 1 0.0004
110 CARDIOTOXICITY 4 0.0004
111 LYMPHOEDEMA 3 0.0004
112 EOSINOPHIL COUNT DECREASED 1 0.0004
113 WEIGHT ABNORMAL 1 0.0004
114 HAEMATOLOGICAL INFECTION 1 0.0004
115 ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 2 0.0004
116 HEPATOSPLENOMEGALY 1 0.0004
117 PRODUCT ADMINISTRATION INTERRUPTED 3 0.0004
118 ILL-DEFINED DISORDER 23 0.0004
119 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 1 0.0004
120 BLOOD POTASSIUM ABNORMAL 1 0.0004
121 ABDOMINAL MASS 1 0.0004
122 MALIGNANT NEOPLASM PROGRESSION 38 0.0004
123 CHOLECYSTITIS INFECTIVE 1 0.0004
124 DRUG TOLERANCE DECREASED 1 0.0004
125 NECK MASS 1 0.0004
126 INFUSION SITE REACTION 1 0.0003
127 ATYPICAL PNEUMONIA 1 0.0003
128 PNEUMONITIS 9 0.0003
129 THERAPEUTIC RESPONSE CHANGED 2 0.0003
130 LOOSE TOOTH 1 0.0003
131 INCORRECT DISPOSAL OF PRODUCT 1 0.0003
132 SUSPECTED COVID-19 1 0.0003
133 NEOPLASM RECURRENCE 1 0.0003
134 FUNCTIONAL GASTROINTESTINAL DISORDER 1 0.0003
135 BLOOD CREATININE ABNORMAL 1 0.0003
136 DEPRESSION SUICIDAL 1 0.0003
137 NEUTROPENIA 39 0.0003
138 FIBRIN D DIMER INCREASED 1 0.0003
139 PANCYTOPENIA 15 0.0003
140 GINGIVAL DISORDER 1 0.0003
141 SPINAL CORD COMPRESSION 1 0.0003
142 PNEUMONIA FUNGAL 1 0.0003
143 GALLBLADDER OPERATION 1 0.0002
144 RECURRENT CANCER 1 0.0002
145 HYPERURICAEMIA 1 0.0002
146 RED CELL DISTRIBUTION WIDTH INCREASED 1 0.0002
147 GASTRIC CANCER 6 0.0002
148 ABSCESS LIMB 1 0.0002
149 ANAL INCONTINENCE 2 0.0002
150 LEUKOPENIA 11 0.0002
151 HAEMOGLOBIN INCREASED 1 0.0002
152 INFUSION RELATED REACTION 14 0.0002
153 MUSCULOSKELETAL DISORDER 4 0.0002
154 HUMERUS FRACTURE 1 0.0002
155 THERAPY CHANGE 2 0.0002
156 INFLAMMATORY MARKER INCREASED 1 0.0002
157 DRUG TOLERANCE 1 0.0002
158 NEUTROPHIL COUNT DECREASED 8 0.0002
159 FAILURE TO THRIVE 1 0.0002
160 OFF LABEL USE 168 0.0002
161 THERAPY NON-RESPONDER 8 0.0002
162 RALES 1 0.0002
163 PERIPHERAL SENSORY NEUROPATHY 1 0.0002
164 COVID-19 30 0.0002
165 C-REACTIVE PROTEIN INCREASED 6 0.0002
166 CARDIAC FAILURE 13 0.0002
167 SEPSIS 18 0.0002
168 PRE-EXISTING CONDITION IMPROVED 1 0.0002
169 WHITE BLOOD CELL COUNT ABNORMAL 1 0.0002
170 HAEMOGLOBIN ABNORMAL 1 0.0002
171 DEAFNESS 4 0.0002
172 PRODUCT PREPARATION ISSUE 1 0.0002
173 ASPERGILLUS INFECTION 1 0.0002
174 INFECTION 22 0.0002
175 APPETITE DISORDER 1 0.0002
176 INTENTIONAL PRODUCT USE ISSUE 13 0.0001
177 METASTASES TO LYMPH NODES 1 0.0001
178 PLEURAL EFFUSION 9 0.0001
179 NEUROPATHY PERIPHERAL 14 0.0001
180 PRODUCT USE ISSUE 27 0.0001
181 LYMPHOPENIA 2 0.0001
182 LYMPHADENOPATHY 5 0.0001
183 METASTASIS 1 0.0001
184 PRODUCT SUPPLY ISSUE 1 0.0001
185 RED BLOOD CELL COUNT DECREASED 4 0.0001
186 MYELODYSPLASTIC SYNDROME 2 0.0001
187 LABORATORY TEST ABNORMAL 4 0.0001
188 BLOOD COUNT ABNORMAL 2 0.0001
189 ASPARTATE AMINOTRANSFERASE INCREASED 7 0.0001
190 GENERAL PHYSICAL HEALTH DETERIORATION 15 0.0001
191 PULMONARY EMBOLISM 12 0.0001
192 HICCUPS 1 0.0001
193 ESCHERICHIA INFECTION 1 0.0001
194 GENERALISED TONIC-CLONIC SEIZURE 2 0.0001
195 EMBOLISM 1 0.0001
196 SECOND PRIMARY MALIGNANCY 1 0.0001
197 CANDIDA INFECTION 2 0.0001
198 FACIAL PARALYSIS 1 0.0001
199 THROMBOCYTOPENIA 13 0.0001
200 BLOOD MAGNESIUM DECREASED 1 0.0001
201 RESPIRATORY TRACT INFECTION 3 0.0001
202 RESPIRATORY SYNCYTIAL VIRUS INFECTION 1 0.0001
203 ALANINE AMINOTRANSFERASE INCREASED 7 0.0001
204 GROIN PAIN 1 0.0001
205 TUMOUR LYSIS SYNDROME 1 0.0001
206 IMMUNOSUPPRESSION 1 0.0001
207 PRODUCT COMMUNICATION ISSUE 1 0.0001
208 OROPHARYNGEAL DISCOMFORT 1 0.0001
209 TREATMENT FAILURE 9 0.0001
210 MENTAL STATUS CHANGES 3 0.0001
211 BACTERIAL INFECTION 2 0.0001
212 OEDEMA PERIPHERAL 13 0.0001
213 FEBRILE NEUTROPENIA 7 0.0001
214 DISEASE RECURRENCE 5 0.0001
215 PNEUMOCYSTIS JIROVECII PNEUMONIA 1 0.0001
216 TOXIC SKIN ERUPTION 1 0.0001
217 FULL BLOOD COUNT DECREASED 2 0.0001
218 PLATELET COUNT DECREASED 10 0.0001
219 LIVER FUNCTION TEST INCREASED 2 0.0001
220 DISTURBANCE IN ATTENTION 5 0.0001
221 INTERNAL HAEMORRHAGE 1 0.0001
222 MYOCARDITIS 1 0.0001
223 ACUTE KIDNEY INJURY 13 0.0001
224 ATAXIA 1 0.0001
225 CHOLECYSTITIS 1 0.0001
226 WHITE BLOOD CELL COUNT DECREASED 9 0.0001
227 ADRENAL INSUFFICIENCY 1 0.0001
228 ENCEPHALOPATHY 2 0.0001
229 GLOMERULAR FILTRATION RATE DECREASED 1 0.0001
230 TENDON RUPTURE 1 0.0001
231 PYREXIA 28 0.0001
232 GENERALISED OEDEMA 1 0.0001
233 DEEP VEIN THROMBOSIS 5 0.0001
234 DEATH 66 0.0001
235 TOOTH INFECTION 1 0.0001
236 HYPOTENSION 15 0.0001
237 HYPOMAGNESAEMIA 1 0.0001
238 MASS 1 0.0001
239 CARPAL TUNNEL SYNDROME 1 0.0001
240 ANOSMIA 1 0.0001
241 HYPERTHYROIDISM 1 0.0001
242 PNEUMONIA 22 0.0001
243 RENAL FAILURE 9 0.0001
244 DRUG EFFECT LESS THAN EXPECTED 1 0.0001
245 INSURANCE ISSUE 1 0.0001
246 LIMB DISCOMFORT 2 0.0001
247 ASTHENIA 24 0.0001
248 HYPOTHYROIDISM 2 0.0001
249 HIP FRACTURE 2 0.0001
250 ATRIAL FIBRILLATION 6 0.0001
251 METASTASES TO BONE 1 0.0001
252 EXPIRED PRODUCT ADMINISTERED 2 0.0001
253 RENAL IMPAIRMENT 5 0.0001
254 MUSCULOSKELETAL DISCOMFORT 1 0.0001
255 PRODUCT DOSE OMISSION ISSUE 17 0.0001
256 HAEMORRHAGE 6 0.0001
257 EOSINOPHILIA 1 0.0001
258 HYPERKALAEMIA 2 0.0001
259 HYPOXIA 2 0.0001
260 ACUTE RESPIRATORY DISTRESS SYNDROME 1 0.0001
261 DRUG ERUPTION 1 0.0001
262 MYELOSUPPRESSION 2 0.0001
263 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 3 0.0001
264 DYSURIA 2 0.0001
265 AGRANULOCYTOSIS 1 0.0001
266 CARDIAC DISORDER 5 0.0001
267 ACUTE RESPIRATORY FAILURE 1 0.0001
268 DRUG INTOLERANCE 5 0.0001
269 PRESCRIBED OVERDOSE 1 0.0001
270 BONE PAIN 3 0.0001
271 KIDNEY INFECTION 1 0.0001
272 ABNORMAL BEHAVIOUR 2 0.0001
273 HAEMATOCRIT DECREASED 1 0.0001
274 BONE MARROW FAILURE 1 0.0000
275 HAEMOGLOBIN DECREASED 5 0.0000
276 PRODUCT PREPARATION ERROR 1 0.0000
277 ANAEMIA 9 0.0000
278 EATING DISORDER 1 0.0000
279 PRODUCT PRESCRIBING ISSUE 1 0.0000
280 CONSTIPATION 10 0.0000
281 CLOSTRIDIUM DIFFICILE INFECTION 1 0.0000
282 GAMMA-GLUTAMYLTRANSFERASE INCREASED 1 0.0000
283 LIVER DISORDER 2 0.0000
284 TOOTH DISORDER 1 0.0000
285 NEOPLASM MALIGNANT 3 0.0000
286 PRODUCT AVAILABILITY ISSUE 1 0.0000
287 RASH 19 0.0000
288 DIARRHOEA 28 0.0000
289 HYPOKALAEMIA 2 0.0000
290 CONFUSIONAL STATE 7 0.0000
291 UPPER RESPIRATORY TRACT INFECTION 2 0.0000
292 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 3 0.0000
293 LOCALISED INFECTION 1 0.0000
294 PNEUMONIA ASPIRATION 1 0.0000
295 CELLULITIS 2 0.0000
296 COUGH 11 0.0000
297 ILLNESS 4 0.0000
298 ABDOMINAL PAIN 9 0.0000
299 HAEMATOMA 1 0.0000
300 MUCOSAL INFLAMMATION 1 0.0000
301 ARTHRITIS 3 0.0000
302 RASH PRURITIC 2 0.0000
303 GASTROINTESTINAL HAEMORRHAGE 3 0.0000
304 HAEMOPTYSIS 1 0.0000
305 DEMENTIA 1 0.0000
306 DRUG INEFFECTIVE 47 0.0000
307 BLISTER 2 0.0000
308 HYPONATRAEMIA 2 0.0000
309 PRODUCT DOSE OMISSION IN ERROR 1 0.0000
310 ANGINA PECTORIS 1 0.0000
311 DYSSTASIA 1 0.0000
312 CHILLS 4 0.0000
313 ASCITES 1 0.0000
314 ACUTE MYOCARDIAL INFARCTION 1 0.0000
315 URINARY INCONTINENCE 1 0.0000
316 RENAL INJURY 1 0.0000
317 RESPIRATORY DISORDER 1 0.0000
318 STOMATITIS 2 0.0000
319 DISCOMFORT 2 0.0000
320 MUSCLE SPASMS 6 0.0000
321 HOSPITALISATION 5 0.0000
322 WEIGHT DECREASED 9 0.0000
323 FATIGUE 25 0.0000
324 NERVOUS SYSTEM DISORDER 1 0.0000
325 DYSPHAGIA 3 0.0000
326 METABOLIC ACIDOSIS 1 0.0000
327 NIGHT SWEATS 1 0.0000
328 BLOOD CREATININE INCREASED 2 0.0000
329 BACK PAIN 7 0.0000
330 SKIN DISORDER 1 0.0000
331 GAIT INABILITY 1 0.0000
332 CEREBROVASCULAR ACCIDENT 5 0.0000
333 HEART RATE DECREASED 1 0.0000
334 PRODUCT USE IN UNAPPROVED INDICATION 7 0.0000
335 ELECTROCARDIOGRAM QT PROLONGED 1 0.0000
336 HYPERGLYCAEMIA 1 0.0000
337 PANIC ATTACK 1 0.0000
338 RESPIRATORY FAILURE 2 0.0000
339 PAIN IN EXTREMITY 8 0.0000
340 INTESTINAL OBSTRUCTION 1 0.0000
341 MUSCULAR WEAKNESS 3 0.0000
342 DECREASED APPETITE 6 0.0000
343 DEPRESSED LEVEL OF CONSCIOUSNESS 1 0.0000
344 DISORIENTATION 1 0.0000
345 JOINT SWELLING 3 0.0000
346 CARDIAC ARREST 2 0.0000
347 POLLAKIURIA 1 0.0000
348 CARDIO-RESPIRATORY ARREST 1 0.0000
349 HYPOACUSIS 1 0.0000
350 CONDITION AGGRAVATED 7 0.0000
351 SEPTIC SHOCK 1 0.0000
352 MENTAL DISORDER 1 0.0000
353 THERAPEUTIC PRODUCT EFFECT DECREASED 1 0.0000
354 LOWER RESPIRATORY TRACT INFECTION 1 0.0000
355 MEMORY IMPAIRMENT 3 0.0000
356 SKIN DISCOLOURATION 1 0.0000
357 OROPHARYNGEAL PAIN 2 0.0000
358 BREAST CANCER 2 0.0000
359 SWELLING 2 0.0000
360 VOMITING 10 0.0000
361 DYSPNOEA 12 0.0000
362 PRODUCTIVE COUGH 1 0.0000
363 BLOOD GLUCOSE DECREASED 1 0.0000
364 HEADACHE 13 0.0000
365 LUNG DISORDER 1 0.0000
366 NAUSEA 16 0.0000
367 SOMNOLENCE 4 0.0000
368 FLUID RETENTION 1 0.0000
369 THERAPY CESSATION 1 0.0000
370 ARTHRALGIA 8 0.0000
371 ECZEMA 1 0.0000
372 MEDICATION ERROR 1 0.0000
373 INFLUENZA 2 0.0000
374 OXYGEN SATURATION DECREASED 1 0.0000
375 URINARY TRACT INFECTION 3 0.0000
376 LETHARGY 1 0.0000
377 DYSPHONIA 1 0.0000
378 NASAL CONGESTION 1 0.0000
379 NO ADVERSE EVENT 3 0.0000
380 THERAPEUTIC RESPONSE DECREASED 1 0.0000
381 CHEST PAIN 3 0.0000
382 DIZZINESS 8 0.0000
383 AMNESIA 1 0.0000
384 DEVICE DIFFICULT TO USE 1 0.0000
385 SLEEP DISORDER 1 0.0000
386 THERAPY INTERRUPTED 1 0.0000
387 BRONCHITIS 1 0.0000
388 DYSGEUSIA 1 0.0000
389 EPISTAXIS 1 0.0000
390 HYPOAESTHESIA 2 0.0000
391 HALLUCINATION 1 0.0000
392 HOT FLUSH 1 0.0000
393 DEPRESSION 3 0.0000
394 BLOOD PRESSURE INCREASED 2 0.0000
395 PRURITUS 5 0.0000
396 PERIPHERAL SWELLING 2 0.0000
397 DRUG DOSE OMISSION BY DEVICE 1 0.0000
398 INJECTION SITE HAEMORRHAGE 1 0.0000
399 CARDIAC FAILURE CONGESTIVE 1 0.0000
400 THROMBOSIS 1 0.0000
401 BALANCE DISORDER 1 0.0000
402 PRODUCT STORAGE ERROR 1 0.0000
403 INSOMNIA 3 0.0000
404 TACHYCARDIA 1 0.0000
405 GASTROINTESTINAL DISORDER 1 0.0000
406 ADVERSE DRUG REACTION 1 0.0000
407 BLOOD GLUCOSE INCREASED 2 0.0000
408 MIGRAINE 1 0.0000
409 CONTUSION 1 0.0000
410 ALOPECIA 2 0.0000
411 HEART RATE INCREASED 1 0.0000
412 FLUSHING 1 0.0000
413 SINUSITIS 1 0.0000
414 ERYTHEMA 2 0.0000
415 ABDOMINAL PAIN UPPER 2 0.0000
416 MALAISE 4 0.0000
417 FALL 3 0.0000
418 ASTHMA 1 0.0000
419 VISUAL IMPAIRMENT 1 0.0000
420 INJECTION SITE ERYTHEMA 1 0.0000
421 HYPERHIDROSIS 1 0.0000
422 PSORIASIS 1 0.0000
423 DEHYDRATION 1 0.0000
424 VISION BLURRED 1 0.0000
425 PAIN 4 0.0000
426 TREMOR 1 0.0000
427 ABDOMINAL DISCOMFORT 1 0.0000
428 TOXICITY TO VARIOUS AGENTS 1 0.0000
429 MYALGIA 1 0.0000
430 MYOCARDIAL INFARCTION 1 0.0000
431 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 1 0.0000
432 NASOPHARYNGITIS 1 0.0000
433 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1 0.0000
434 HYPERTENSION 1 0.0000
435 WEIGHT INCREASED 1 0.0000
436 FEELING ABNORMAL 1 0.0000